Publications des scientifiques de l'IRD

Sripan Patumrat, Le Coeur S., Ingsrisawang L., Cressey T. R., Bouazza N., Foissac F., Ngo-Giang-Huong Nicole, Traisathit P., Srirompotong U., Ayudhaya O. P. N., Puangsombat A., Jungpipun J., Jittayanun K., Treluyer J. M., Jourdain Gonzague, Lallemant Marc, Urien S. (2016). Contribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir-boosted lopinavir on HIV viral load reduction during pregnancy. Antiviral Therapy, 21 (5), p. 435-440. ISSN 1359-6535.

Titre du document
Contribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir-boosted lopinavir on HIV viral load reduction during pregnancy
Année de publication
2016
Type de document
Article référencé dans le Web of Science WOS:000396089500008
Auteurs
Sripan Patumrat, Le Coeur S., Ingsrisawang L., Cressey T. R., Bouazza N., Foissac F., Ngo-Giang-Huong Nicole, Traisathit P., Srirompotong U., Ayudhaya O. P. N., Puangsombat A., Jungpipun J., Jittayanun K., Treluyer J. M., Jourdain Gonzague, Lallemant Marc, Urien S.
Source
Antiviral Therapy, 2016, 21 (5), p. 435-440 ISSN 1359-6535
Background: Antiretroviral (ARV) regimens used for the prevention of mother-to-child transmission of HIV have evolved over time. We evaluated the contribution of different ARV regimens on the reduction of the plasma HIV RNA viral load (VL) during pregnancy. Methods: A total of 1,833 VL measurements from ARV-naive pregnant women participating in perinatal prevention trials in Thailand were included. Women received either zidovudine (ZDV) monotherapy, ZDV plus lopinavir/ritonavir (LPV/r), or ZDV plus lamivudine (3TC) plus LPV/r. VL time-course during pregnancy was described as a function of pretreatment VL and treatment duration using an E max non-linear mixed-effect model. VL reduction and median time to achieve a VL< 50 copies/ml were estimated for each regimen. Results: Among 745 women, 279 (37%), 145 (20%) and 321 (43%) received ZDV monotherapy, ZDV+ LPV/r and ZDV+ 3TC+ LPV/r, respectively. The predicted VL reduction from baseline to delivery after a median of 10 weeks of treatment were 0.5, 2.7 and 2.9 log 10 copies/ml with ZDV monotherapy, ZDV+ LPV/r and ZDV+ 3TC+ LPV/r, respectively. At delivery, 1%, 57% and 63% of women receiving ZDV monotherapy, ZDV+ LPV/r or ZDV+ 3TC+ LPV/r had a VL< 50 copies/ml. The addition of 3TC to ZDV+ LPV/r reduced the time to achieve a VL< 50 copies/ml and the higher the pretreatment VL, the larger the effect 3TC had on reducing the time to VL< 50 copies/ml. Conclusions: The addition of 3TC to ZDV+ LPV/r was associated with a slight further VL reduction but the time to reach a VL< 50 copies/ml was shorter. This beneficial effect of 3TC is crucial for prevention of mother-to-child transmission in women who receive ARVs late and with high pretreatment VL.
Plan de classement
Santé : généralités [050] ; Entomologie médicale / Parasitologie / Virologie [052]
Description Géographique
THAILANDE
Localisation
Fonds IRD [F B010069356]
Identifiant IRD
fdi:010069356
Contact